Stay updated on Quizartinib-Decitabine-Venetoclax Combo in AML Clinical Trial
Sign up to get notified when there's something new on the Quizartinib-Decitabine-Venetoclax Combo in AML Clinical Trial page.

Latest updates to the Quizartinib-Decitabine-Venetoclax Combo in AML Clinical Trial page
- Check3 days agoChange DetectedThe ClinicalTrials.gov site footer revision changes from v3.7.0 to v3.7.1.SummaryDifference0.1%

- Check10 days agoChange DetectedThe record history now includes Eligibility and Study Status sections, and shows a change dated 2026-09-22 with 40 changes, while a prior entry dated 2026-08-20 was deleted.SummaryDifference0.3%

- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedThe added entries include a lowercase 'Find contact information' label and a new 'Revision: v3.7.0' tag, while the previous uppercase 'Find Contact Information' and 'Revision: v3.6.6' entries are removed.SummaryDifference0.1%

- Check31 days agoChange DetectedA new version entry was added to the study's record history, indicating that the trial listing has been updated since the previous version. This is a log-level change reflecting maintenance of the record rather than a substantive change to the study's details.SummaryDifference0.1%

- Check38 days agoChange DetectedA new revision entry (v3.6.6) was added to the Record History and the previous revision (v3.6.5) was removed, reflecting a metadata update to the page’s version history.SummaryDifference0.1%

- Check45 days agoChange DetectedThe version history now shows a new entry on 2026-08-20 adding study status and recruitment-related sections (Recruiting, Recruitment Status, Contacts/Locations, Study Status) and 2026-08-19 (version 39). Deletions on 2026-07-21 remove Suspended and PI Request notes.SummaryDifference0.6%

Stay in the know with updates to Quizartinib-Decitabine-Venetoclax Combo in AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Quizartinib-Decitabine-Venetoclax Combo in AML Clinical Trial page.